ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Oct 31, 2016 23:00 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma Completes Acquisition of Reputable Generic Drug Manufacturer in Hong Kong
HONG KONG, Oct 31, 2016 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines and the largest generic drug company in Hong Kong, today announces the completion of the acquisition of Cawah Holdings Limited ("Cawah Holdings") and its subsidiary namely, Medipharma Limited ("Medipharma") which is a reputable generic drug manufacturer in Hong Kong, at a total consideration of HK$100,000,000.
Medipharma is principally engaged in the manufacturing and sale of generic drugs in Hong Kong. With a decent market share in both the public and private sectors in the Hong Kong generic drug market, Cawah Holdings and its subsidiary Medipharma recorded an unaudited net profit after taxation and extraordinary items for the financial year ended 31 December 2015 and for the eight months ended 31 August 2016 of HK$10,013,000 and HK$ 9,457,000, respectively.
Upon completion of the acquisition, Cawah Holdings and Medipharma will become indirect wholly-owned subsidiaries of the Group and the financial results will be consolidated.
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma said, "Riding on our strategic plan to drive sustainable business growth and generate impactful synergies through targeted mergers and acquisitions, I am pleased to announce the completion of this meaningful acquisition deal. The products portfolio of Medipharma, is highly complementary to that of the Group, thus providing us with an avenue to achieve sustainable growth and earnings visibility."
"Through the acquisition, we will further deepen our penetration in both public and private sectors, as well as attaining greater diversity in terms of product offerings. Such efforts will enable us to further consolidate Jacobson Pharma's leadership position in the generic drug market in Hong Kong. Going forward, we will continue to maximize the growth momentum by unlocking the full value of our acquisitions."
The Consideration for the Acquisition is HK$100,000,000, of which HK$10,000,000 is allocated as consideration for the Operating Assets; and HK$90,000,000 is allocated as consideration for the Sale of Shares. The Consideration will be funded by internal resources of the Group and bank borrowings.
About Jacobson Pharma Corporation Limited
Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012 according to Frost & Sullivan. The Group's proprietary Chinese medicines, notable ones being Po Chai Pills and Tong Tai Chung Woodlok Oil are widely carried in the market. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: +852 2864 4834 Email:
vicky.lee@sprg.com.hk
Angela Ng Tel: +852 2864 4855 Email:
angela.ng@sprg.com.hk
Angel Li Tel: +852 2864 4859 Email:
angelok.li@sprg.com.hk
Fax: +852 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, Daily News, BioTech
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project
Apr 12, 2024 14:39 JST
MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors
Apr 11, 2024 18:08 JST
Mitsubishi Shipbuilding Acquires Approval in Principle (AiP) from Classification Society ClassNK for Ammonia Fuel Supply System (AFSS)
Apr 11, 2024 17:50 JST
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 11, 2024 15:10 JST
Mitsubishi Corporation Announces Completion of Capital Raise by Nexamp
Apr 11, 2024 13:07 JST
Mitsubishi Shipbuilding Receives Order for Ammonia Fuel Supply System for Ammonia-Powered Marine Engine
Apr 10, 2024 16:55 JST
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 10, 2024 13:36 JST
DENSO, Companies Initiate Demonstration to Expand Automotive Recycling Process
Apr 09, 2024 19:07 JST
Mitsubishi Power Receives Order from HK Electric for Natural-gas-fired GTCC Power Generation Equipment
Apr 09, 2024 15:04 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
March 14 2022 19:58 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
Jacobson Pharma Announces FY2021 Interim Results
November 27 2020 20:10 JST
More Press release >>